News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
484,091 Results
Type
Article (8047)
Company Profile (140)
Press Release (475999)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166767)
Career Advice (305)
Deals (25742)
Drug Delivery (7)
Drug Development (52887)
Employer Resources (14)
FDA (9762)
Job Trends (8577)
News (238260)
Policy (17925)
Tag
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (4)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (488)
Accelerated approval (24)
ADA (18)
Adcomms (1)
Allergies (96)
Alliances (33162)
ALS (104)
Alzheimer's disease (972)
Antibody-drug conjugate (ADC) (262)
Approvals (10366)
Artificial intelligence (317)
ASCO (159)
Autoimmune disease (205)
Automation (28)
Bankruptcy (262)
Best Places to Work (6965)
BIO (36)
BIOSECURE Act (1)
Biosimilars (108)
BioSpace Insights (17)
Biotechnology (88)
Bladder cancer (138)
Brain cancer (28)
Breast cancer (505)
Cancer (3618)
Cardiovascular disease (217)
Career advice (246)
Career pathing (1)
CAR-T (172)
Celiac Disease (1)
Cell therapy (474)
Cervical cancer (34)
Clinical research (47835)
Collaboration (1231)
Commercialization (2)
Compensation (1436)
Complete response letters (34)
COVID-19 (757)
CRISPR (63)
C-suite (731)
Cystic fibrosis (85)
Data (5590)
Denatured (4)
Depression (102)
Dermatology (60)
Diabetes (339)
Diagnostics (4174)
Digital health (37)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (154)
Drug pricing (7)
Drug shortages (2)
Duchenne muscular dystrophy (163)
Earnings (73468)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (87577)
Executive appointments (696)
FDA (12355)
Fibrodysplasia Ossificans Progressiva (8)
Friedreich's ataxia (18)
Frontotemporal dementia (23)
Funding (903)
Gene editing (125)
Generative AI (9)
Gene therapy (315)
GLP-1 (290)
Government (950)
Grass and pollen (2)
Guidances (280)
Healthcare (9323)
Hematology (94)
HIV (52)
Huntington's disease (22)
IgA nephropathy (64)
Immunology and inflammation (98)
Immuno-oncology (56)
Indications (155)
Infectious disease (945)
Inflammatory bowel disease (126)
Inflation Reduction Act (4)
Influenza (84)
Intellectual property (250)
Interviews (42)
IPO (12387)
IRA (2)
Job creations (1968)
Job search strategy (235)
JPM (1)
Kidney cancer (16)
Layoffs (59)
Legal (5209)
Licensing (7)
Liver cancer (44)
Longevity (15)
Lung cancer (501)
Lymphoma (248)
Machine learning (27)
Management (3)
Manufacturing (524)
Marketing (7)
MASH (117)
Medical device (8649)
Medtech (8787)
Mergers & acquisitions (14377)
Metabolic disorders (699)
mRNA (53)
Multiple sclerosis (102)
NASH (4)
Neurodegenerative disease (218)
Neuropsychiatric disorders (38)
Neuroscience (1812)
NextGen: Class of 2026 (3154)
Non-profit (846)
Obesity (221)
Opinion (10)
Ovarian cancer (158)
Pain (170)
Pancreatic cancer (194)
Parkinson's disease (200)
Partnered (11)
Patents (465)
Patient recruitment (497)
Peanut (31)
People (41210)
Pharmaceutical (30)
Pharmacy benefit managers (8)
Phase 1 (15457)
Phase 2 (21363)
Phase 3 (14390)
Pipeline (7021)
Policy (18)
Postmarket research (1572)
Preclinical (6534)
Press Release (34)
Prostate cancer (189)
Psychedelics (7)
Radiopharmaceuticals (189)
Rare diseases (568)
Real estate (3021)
Recruiting (6)
Regulatory (14785)
Reports (17)
Research institute (581)
Resumes & cover letters (46)
Rett syndrome (41)
RNA editing (5)
RSV (48)
Schizophrenia (99)
Series A (153)
Series B (119)
Service/supplier (5)
Sickle cell disease (62)
Spinal muscular atrophy (88)
Sponsored (5)
Startups (2018)
Stomach cancer (3)
Supply chain (50)
Vaccines (317)
Venture capital (17)
Weight loss (73)
Women's health (78)
Date
Today (85)
Last 7 days (540)
Last 30 days (1485)
Last 365 days (19111)
2026 (11704)
2025 (19251)
2024 (22988)
2023 (26543)
2022 (34600)
2021 (37172)
2020 (33471)
2019 (23257)
2018 (17494)
2017 (18767)
2016 (17922)
2015 (24264)
2014 (21679)
2013 (18139)
2012 (20221)
2011 (20441)
2010 (20332)
Location
Africa (227)
Alabama (72)
Alaska (2)
Arizona (299)
Arkansas (11)
Asia (17874)
Australia (2095)
California (11789)
Canada (3097)
China (512)
Colorado (476)
Connecticut (402)
Delaware (206)
Europe (24614)
Florida (1762)
Georgia (370)
Hawaii (3)
Idaho (46)
Illinois (691)
India (45)
Indiana (314)
Iowa (14)
Japan (395)
Kansas (99)
Kentucky (30)
Louisiana (26)
Maine (25)
Maryland (1181)
Massachusetts (7775)
Michigan (305)
Minnesota (555)
Mississippi (4)
Missouri (79)
Montana (20)
Nebraska (11)
Nevada (113)
New Hampshire (60)
New Jersey (2589)
New Mexico (12)
New York (2787)
North Carolina (1256)
North Dakota (4)
Northern California (5890)
Ohio (273)
Oklahoma (14)
Oregon (16)
Pennsylvania (2231)
Puerto Rico (20)
Rhode Island (30)
South America (406)
South Carolina (76)
South Dakota (1)
Southern California (4897)
Tennessee (117)
Texas (1902)
United States (38343)
Utah (357)
Vermont (1)
Virginia (151)
Washington D.C. (38)
Washington State (911)
West Virginia (1)
Wisconsin (73)
484,091 Results for "chiasma inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Tevogen Bio Holdings Inc. Becomes Tevogen Inc.
July 29, 2026
·
4 min read
Drug Development
Chiasma to Present New Data from Two Phase 3 Trials, CHIASMA OPTIMAL and MPOWERED™, at ENDO 2021
Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases currently treated with burdensome and painful injections, as evidenced by its recent approval of MYCAPSSA as the first and only oral therapy for the treatment of acromegaly
March 10, 2021
·
9 min read
Drug Development
Chiasma Presents Positive Patient-Reported Outcomes Data from its MPOWERED™ Phase 3 Trial
Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”) today presented patient-reported outcomes (PROs) data from its MPOWERED™ Phase 3 trial demonstrating that study patients with acromegaly reported significantly improved quality of life and work productivity after transitioning from long-acting injectable somatostatin analogs (iSSAs) to MYCAPSSA ® .
May 27, 2021
·
8 min read
Genetown
Amryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc.
Amryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc.
June 15, 2021
·
14 min read
Drug Development
Chiasma Presents Long-Term Safety and Efficacy Data from the Open-Label Extension Study of its CHIASMA OPTIMAL Phase 3 Trial Evaluating MYCAPSSA® in Patients with Acromegaly at ENDO 2021
Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases currently treated with burdensome and painful injections, as evidenced by its recent phased launch of MYCAPSSA®
March 22, 2021
·
8 min read
Drug Development
Chiasma Announces Publication of Pivotal Data from the Phase 3 CHIASMA OPTIMAL Clinical Trial in the Journal of Clinical Endocrinology & Metabolism
Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop oral therapies to reduce the burden of chronic injections for people with rare diseases, today announced the online publication of its CHIASMA OPTIMAL (Octreotide capsules vs. Placebo Treatment In MultinationAL centers) Phase 3 clinical tria
August 17, 2020
·
7 min read
Press Releases
FOXO TECHNOLOGIES INC.’S SUBSIDIARY VECTOR BIOSOURCE, INC. ENTERS INTO DEFINITIVE AGREEMENT TO ACQUIRE FOUR BLOOD COLLECTION CENTERS FROM GRIFOLS BIO SUPPLIES, INC.
July 29, 2026
·
6 min read
Deals
Amryt and Chiasma Combine to Form Rare and Orphan Diseases Powerhouse
Amryt inked an all-stock acquisition deal with Chiasma. The combined company will focus on rare and orphan diseases with three marketed products and a strong development pipeline.
May 5, 2021
·
3 min read
·
Mark Terry
Business
Chiasma Announces Hiring of John Doyle as Chief Financial OfficerAppointment provides extensive commercial-stage public company financial leadership experience
Chiasma, Inc. announced the hiring of John Doyle as its new Chief Financial Officer
January 19, 2021
·
6 min read
Business
Chiasma to Report First Quarter Financial Results on May 6, 2021
Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Thursday, May 6, 2021 at 5:00 pm Eastern Time to discuss financial results for the quarter ended March 31, 2021 and to provide a business update.
April 29, 2021
·
1 min read
1 of 48,410
Next
